Today, LifeBioSciences team confirmed the first patient has been dosed with an epigenetic restoration drug candidate targeting optic neuropathies. "An exciting milestone"
Summary
LifeBioSciences has dosed the first patient in a Phase 1 trial of ER-100, an epigenetic restoration drug candidate for optic neuropathies, marking a milestone in the development of therapies for vision impairment.
Similar Articles
Longevity Startup Doses First Human in Bid to Reverse Age-Related Sight Loss
Life Biosciences has dosed its first patient with ER-100, a cellular rejuvenation therapy aiming to reverse age-related sight loss, in a first-ever human clinical trial approved by the FDA.
World-first: therapy to make cells young again given to a person
First person treated in a gene therapy trial using partial reprogramming to rejuvenate cells, aiming to treat glaucoma by regenerating optic nerve neurons.
Why “reprogramming” is the buzziest approach to reversing aging right now
A biotech company has dosed its first volunteer in a clinical trial for an experimental glaucoma treatment that uses cellular reprogramming to reverse age-related damage, part of a broader trend toward rejuvenation therapies.
David Sinclair plans to test whole-body rejuvenation drugs in the XPrize competition
David Sinclair plans to test an oral epigenetic reprogramming drug, SL-100, in the XPrize competition for whole-body rejuvenation, aiming for a 10-year age reversal.
UCLA discovers first stroke rehabilitation drug to repair brain damage (2025)
UCLA researchers developed DDL-920, a drug mimicking stroke rehabilitation effects in mice, published in Nature Communications. This breakthrough targets parvalbumin neurons to restore gamma oscillations and improve movement control.